Anticholinesterase effects of huperzine A, E2020, and tacrine in rats

Acta Pharmacologica Sinica

Volumn 19, Issue 1, 1998, Pages 27-30

  Wang, Hong ^a   Tang, Xi Can ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cholinesterase inhibitors; Cholinesterases; E2020; Huperzine A; Tacrine

Indexed keywords

BRAIN ENZYME; BUTYRYLTHIOCHOLINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; HUPERZINE A; TACRINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FASCICULATION; INTRAGASTRIC DRUG ADMINISTRATION; NONHUMAN; RAT; SALIVATION; SPECTROPHOTOMETRY; STEADY STATE; TREMOR;

ACETYLCHOLINESTERASE; ANIMALS; BRAIN; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INDANS; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; TACRINE;

EID: 0031883728     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Coyle JT, Price DL, Delong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1963; 219: 1184-90.
2. Pomponi M, Giacobini E, Brufani M. Present state and future development of the therapy of Alzheimer disease. Aging 1990; 2: 125-53.
3. Mohs RC, Davis BM, Johns CA, Mathé AA, Greenwald BS, Horvath TB, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142: 28-33.
4. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-5.
5. Winblad B, Adem A, Backman L, Nordberg A, Elinder F, Arhem P. Cholinesterase inhibitors in Alzheimer's disease: Evaluation of Clinical Studies. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser; 1991. p 238-43.
6. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-8.
7. Tang XC. Huperzine A (Shuangyiping): a promising drug for Alzheimer's disease. Acta Pharmacol Sin 1996; 17: 481-4.
8. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser; 1991. p 314-20.
9. Ellman GL, Couitney KD, Andre V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
10. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
11. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 1996; 8: 97-101.
12. Cheng DH, Tang XC. Comparative studies of Huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1996; 61: in press.
13. Yoshiharu Y, Hiroo O, Takashi K, Shin A, Yoshio S, Kiyomi Y. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors. In: Nagatsu T, Fisher A, Yoshida M, editors. Basic, clinical, and therapeutic aspects of Alzheimer's and Parkinson's diseases. Vol 2. New York: Plenum; 1991. p 409-13.
14. Laganière S, Corey J, Tang XC, Wülfert E, Hanin I. Acute and chronic studies with the anticholinesterase huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology 1991; 30: 763-8.
15. Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989; 28: 199-206.